metformin has been researched along with Infarct in 5 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study suggests that the prolonged effect of metformin-induced euglycemia promoted the microglial activation, reduced neuronal cell death, and improved the overall survival following stroke, without any change in infarct size." | 8.12 | The effect of chronic exposure to metformin in a new type-2 diabetic NONcNZO10/LtJ mouse model of stroke. ( Kimball, SR; Kumari, R; Simpson, IA; Willing, L, 2022) |
| "The study suggests that the prolonged effect of metformin-induced euglycemia promoted the microglial activation, reduced neuronal cell death, and improved the overall survival following stroke, without any change in infarct size." | 4.12 | The effect of chronic exposure to metformin in a new type-2 diabetic NONcNZO10/LtJ mouse model of stroke. ( Kimball, SR; Kumari, R; Simpson, IA; Willing, L, 2022) |
| " Two known AMPK activators (metformin and AICAR) were used to verify the hypothesis that a transitory activation of AMPK at reperfusion may exert cardioprotection, as reflected in a reduction in myocardial infarct size." | 3.76 | Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction. ( Davidson, SM; Gonçalves, LM; Mocanu, MM; Paiva, MA; Providência, LA; Yellon, DM, 2010) |
| "Thirty (39%) patients suffered cardiac arrest before admission." | 1.43 | Prognosis of patients presenting extreme acidosis (pH <7) on admission to intensive care unit. ( Allou, N; Allyn, J; Brulliard, C; Combe, P; Galliot, R; Jabot, J; Martinet, O; Tabatchnik, X; Vandroux, D, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kuburas, R | 1 |
| Gharanei, M | 1 |
| Haussmann, I | 1 |
| Maddock, H | 1 |
| Sandhu, H | 1 |
| Kumari, R | 1 |
| Willing, L | 1 |
| Kimball, SR | 1 |
| Simpson, IA | 1 |
| Melendez, GC | 1 |
| Chen, Q | 1 |
| Lesnefsky, EJ | 1 |
| Allyn, J | 1 |
| Vandroux, D | 1 |
| Jabot, J | 1 |
| Brulliard, C | 1 |
| Galliot, R | 1 |
| Tabatchnik, X | 1 |
| Combe, P | 1 |
| Martinet, O | 1 |
| Allou, N | 1 |
| Paiva, MA | 1 |
| Gonçalves, LM | 1 |
| Providência, LA | 1 |
| Davidson, SM | 1 |
| Yellon, DM | 1 |
| Mocanu, MM | 1 |
5 other studies available for metformin and Infarct
| Article | Year |
|---|---|
Metformin Protects Against Sunitinib-induced Cardiotoxicity: Investigating the Role of AMPK.
Topics: Adenylate Kinase; AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Cardiotoxicity; | 2022 |
The effect of chronic exposure to metformin in a new type-2 diabetic NONcNZO10/LtJ mouse model of stroke.
Topics: AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; H | 2022 |
Metformin as a modulator of myocardial fibrosis postmyocardial infarction via regulation of cardiomyocyte-fibroblast crosstalk.
Topics: Fibroblasts; Fibrosis; Humans; Infarction; Metformin; Myocardial Infarction; Myocardium; Myocytes, C | 2018 |
Prognosis of patients presenting extreme acidosis (pH <7) on admission to intensive care unit.
Topics: Acidosis; Acidosis, Lactic; Acidosis, Respiratory; Adult; Aged; Diabetes Mellitus; Extracorporeal Me | 2016 |
Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Enzyme Activation; Heart; Hemody | 2010 |